The purpose of this expanded access program (EAP) is to provide access to apitegromab for eligible patients with spinal muscular atrophy (SMA) prior to approval by the local regulatory agency . A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-10.
Status change: Available → No Longer Available2026-04-23